Cargando…
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
Acute myeloid leukemia (AML) is a heterogenous and complex disease characterized by rapid cellular proliferation, an aggressive clinical course, and generally high mortality. While progress has been made in the understanding of the genetic and molecular biology of the disease, the standard of care f...
Autores principales: | Winer, Eric S., Stone, Richard M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624910/ https://www.ncbi.nlm.nih.gov/pubmed/31321011 http://dx.doi.org/10.1177/2040620719860645 |
Ejemplares similares
-
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023) -
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012) -
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020) -
New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020) -
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)